231 related articles for article (PubMed ID: 36622326)
21. Monitoring Treatment-Free Remission by Droplet Digital PCR in CML Patients with Deep Molecular Response to Tyrosine Kinase Inhibitor: An Analysis Based on Real-World Data.
Zhu G; Yang Y; Wang H; Xie J; Hu J; Guo W; Zhang L; Liu Z; Chen X; Chang J; Xu J; Tan Y
Ann Clin Lab Sci; 2020 Sep; 50(5):591-599. PubMed ID: 33067205
[TBL] [Abstract][Full Text] [Related]
22. Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study.
Jin S; Shang Z; Wang W; Gu C; Wei Y; Zhu Y; Yang C; Zhang T; Zhu Y; Zhu Y; Wu J; Ye D
J Immunother; 2023 May; 46(4):154-159. PubMed ID: 37017991
[TBL] [Abstract][Full Text] [Related]
23. Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.
Hughes A; Yong ASM
Front Immunol; 2017; 8():469. PubMed ID: 28484463
[TBL] [Abstract][Full Text] [Related]
24. Infliximab modifies regulatory T cells and co-inhibitory receptor expression on circulating T cells in psoriasis.
Yu Y; Chen Z; Wang Y; Li Y; Lu J; Cui L; Yu Z; Ding Y; Guo C; Zhang X; Shi Y
Int Immunopharmacol; 2021 Jul; 96():107722. PubMed ID: 33965878
[TBL] [Abstract][Full Text] [Related]
25. Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
Rodrigues-Santos P; López-Sejas N; Almeida JS; Ruzičková L; Couceiro P; Alves V; Campos C; Alonso C; Tarazona R; Freitas-Tavares P; Solana R; Santos-Rosa M
Front Immunol; 2018; 9():2587. PubMed ID: 30487792
[TBL] [Abstract][Full Text] [Related]
26. NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
Almeida JS; Couceiro P; López-Sejas N; Alves V; Růžičková L; Tarazona R; Solana R; Freitas-Tavares P; Santos-Rosa M; Rodrigues-Santos P
Front Immunol; 2019; 10():2493. PubMed ID: 31695700
[TBL] [Abstract][Full Text] [Related]
27. Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission.
Dumas PY; Bérard E; Bréal C; Dulucq S; Réa D; Nicolini F; Forcade E; Dufossée M; Pasquet JM; Turcq B; Bidet A; Milpied N; Déchanet-Merville J; Lafarge X; Etienne G; Mahon FX;
Cancer Med; 2019 Sep; 8(11):4976-4985. PubMed ID: 31287239
[TBL] [Abstract][Full Text] [Related]
28. Treatment-free remission and immunity in chronic myeloid leukemia.
Ureshino H
Int J Hematol; 2021 May; 113(5):642-647. PubMed ID: 33651270
[TBL] [Abstract][Full Text] [Related]
29. Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis.
Lavon I; Heli C; Brill L; Charbit H; Vaknin-Dembinsky A
Front Immunol; 2019; 10():835. PubMed ID: 31134049
[No Abstract] [Full Text] [Related]
30. TIGIT expression is upregulated in T cells and causes T cell dysfunction independent of PD-1 and Tim-3 in adult B lineage acute lymphoblastic leukemia.
Zhang X; Zhang H; Chen L; Feng Z; Gao L; Li Q
Cell Immunol; 2019 Oct; 344():103958. PubMed ID: 31376919
[TBL] [Abstract][Full Text] [Related]
31. Allelic polymorphisms of
Shindo T; Ureshino H; Kojima H; Tanaka H; Kimura S
Immunol Med; 2021 Jun; 44(2):61-68. PubMed ID: 32715973
[TBL] [Abstract][Full Text] [Related]
32. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.
Cai L; Li Y; Tan J; Xu L; Li Y
J Hematol Oncol; 2023 Sep; 16(1):101. PubMed ID: 37670328
[TBL] [Abstract][Full Text] [Related]
33. Increased TOX expression concurrent with PD-1, Tim-3, and CD244 expression in T cells from patients with acute myeloid leukemia.
Huang S; Liang C; Zhao Y; Deng T; Tan J; Zha X; Li Y; Chen S
Cytometry B Clin Cytom; 2022 Mar; 102(2):143-152. PubMed ID: 34913594
[TBL] [Abstract][Full Text] [Related]
34. Case report: CD38-directed CAR-T cell therapy: A novel immunotherapy targeting CD38- positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase.
Cui Q; Liang P; Dai H; Cui W; Cai M; Ding Z; Ma Q; Yin J; Li Z; Liu S; Kang L; Yao L; Cen J; Shen H; Zhu M; Yu L; Wu D; Tang X
Front Immunol; 2022; 13():1012981. PubMed ID: 36524116
[TBL] [Abstract][Full Text] [Related]
35. Model-Based Inference and Classification of Immunologic Control Mechanisms from TKI Cessation and Dose Reduction in Patients with CML.
Hähnel T; Baldow C; Guilhot J; Guilhot F; Saussele S; Mustjoki S; Jilg S; Jost PJ; Dulucq S; Mahon FX; Roeder I; Fassoni AC; Glauche I
Cancer Res; 2020 Jun; 80(11):2394-2406. PubMed ID: 32041835
[TBL] [Abstract][Full Text] [Related]
36. Expression of the immune checkpoint receptors CTLA-4, LAG-3, and TIM-3 in β-thalassemia major patients: correlation with alloantibody production and regulatory T cells (Tregs) phenotype.
Shokrgozar N; Karimi M; Golmoghaddam H; Rezaei N; Moayed V; Sharifzadeh S; Arandi N
Ann Hematol; 2021 Oct; 100(10):2463-2469. PubMed ID: 34324022
[TBL] [Abstract][Full Text] [Related]
37. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
[TBL] [Abstract][Full Text] [Related]
38. Different aberrant expression pattern of immune checkpoint receptors in patients with PTCL and NK/T-CL.
Liao Z; Lv X; Liu S; He Z; Chen S; Wang L; Li W; Li Y
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e252-e258. PubMed ID: 29368793
[TBL] [Abstract][Full Text] [Related]
39. Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy.
Söderlund S; Persson I; Ilander M; Guilhot J; Hjorth-Hansen H; Koskenvesa P; Richter J; Saussele S; Mustjoki S; Olsson-Strömberg U
Leuk Res; 2020 Mar; 90():106310. PubMed ID: 32058176
[TBL] [Abstract][Full Text] [Related]
40. In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy.
Sanchez MB; Vasconcelos Cordoba B; Pavlovsky C; Moiraghi B; Varela A; Custidiano R; Fernandez I; Freitas MJ; Ventriglia MV; Bendek G; Mariano R; Mela Osorio MJ; Pavlovsky MA; García de Labanca A; Foncuberta C; Giere I; Vera M; Juni M; Mordoh J; Sanchez Avalos JC; Levy EM; Bianchini M
Front Immunol; 2023; 14():1241600. PubMed ID: 37818372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]